for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Caladrius Biosciences Inc

CLBS.OQ

Latest Trade

2.32USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

2.03

 - 

5.40

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Caladrius Biosciences Reports Q2 Loss Per Share $0.49

Aug 8 (Reuters) - Caladrius Biosciences Inc <CLBS.O>::CALADRIUS BIOSCIENCES REPORTS 2019 SECOND QUARTER AND FIRST SIX MONTHS FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.49.AS OF JUNE 30, 2019, CALADRIUS HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $33.7 MILLION.

Caladrius Biosciences Reports Q3 Loss Per Share Of $0.36 From Continuing Operations

Nov 8 (Reuters) - Caladrius Biosciences Inc <CLBS.O>::CALADRIUS BIOSCIENCES REPORTS 2018 THIRD QUARTER FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.36 FROM CONTINUING OPERATIONS.CALADRIUS BIOSCIENCES - AS OF SEPT 30 CO HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $46.1 MILLION VERSUS $60.1 MILLION AS OF DEC 31, 2017.CALADRIUS BIOSCIENCES - EXPECTS CASH BALANCE WILL ALLOW CO TO FUND CURRENT BUSINESS PLAN BEYOND 2019.

Caladrius Biosciences Q2 Loss Per Share $0.42 From Continuing Operations

Caladrius Biosciences Inc <CLBS.O>::CALADRIUS BIOSCIENCES REPORTS 2018 SECOND QUARTER AND FIRST SIX MONTHS FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.42 FROM CONTINUING OPERATIONS.AS OF JUNE 30, 2018, CO HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $50.3 MILLION.

Caladrius Biosciences Files For Mixed Shelf Of Upto $150 Mln

July 24 (Reuters) - Caladrius Biosciences Inc <CLBS.O>::CALADRIUS BIOSCIENCES INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.

Caladrius Biosciences Reports Q1 Loss Per Share $0.52 From Continuing Operations

May 10 (Reuters) - Caladrius Biosciences Inc <CLBS.O>::CALADRIUS BIOSCIENCES REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.52 FROM CONTINUING OPERATIONS.

Caladrius Biosciences Q4 Loss Per Share $0.40 From Cont Ops

March 22 (Reuters) - Caladrius Biosciences Inc <CLBS.O>::CALADRIUS BIOSCIENCES REPORTS 2017 FOURTH QUARTER AND YEAR END FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.40 FROM CONTINUING OPERATIONS.CALADRIUS - ‍AS OF DEC 31, 2017, CO HAD CASH, CASH EQUIVALENTS, RESTRICTED CASH AND MARKETABLE SECURITIES OF $60.1 MILLION VERSUS $7.1 MILLION AS OF DEC 31, 2016​.CALADRIUS BIOSCIENCES - ‍CONFIDENT THAT CASH BALANCES, ADDITIONAL GRANT FUNDING WILL ALLOW IT TO FUND ITS CURRENT BUSINESS PLAN BEYOND 2019​.

Caladrius Biosciences Acquires Exclusive Worldwide Rights To Data Set, Regulatory Filings For CD34+ Cell Therapy Program

March 6 (Reuters) - Caladrius Biosciences Inc <CLBS.O>::CALADRIUS BIOSCIENCES ACQUIRES AN EXCLUSIVE LICENSE TO A LATE STAGE CD34+ CELL THERAPY PROGRAM FOR THE TREATMENT OF REFRACTORY ANGINA.CALADRIUS BIOSCIENCES INC - UNDER DEAL TERMS , ACQUIRED EXCLUSIVE WORLDWIDE RIGHTS TO DATA SET, REGULATORY FILINGS FOR CD34+ CELL THERAPY PROGRAM.CALADRIUS BIOSCIENCES INC - IN EXCHANGE, SHIRE WILL RECEIVE UNDISCLOSED UP-FRONT CONSIDERATION, MILESTONES AND A ROYALTY ON PRODUCT SALES.CALADRIUS BIOSCIENCES INC - ACQUIRED FROM SHIRE PLC AN EXCLUSIVE WORLDWIDE LICENSE TO DATA FROM A LATE STAGE CD34+ CELL THERAPY PROGRAM.

Caladrius Biosciences Entered Common Stock Sales Agreement With H.C. Wainwright & Co

Feb 8 (Reuters) - Caladrius Biosciences Inc <CLBS.O>::CALADRIUS BIOSCIENCES INC - ENTERED INTO A COMMON STOCK SALES AGREEMENT WITH H.C. WAINWRIGHT & CO HAVING AGGREGATE OFFERING PRICE OF UP TO $12 MILLION.

Caladrius Biosciences Announces Completion Of Enrollment Of Phase 2 T-Rex Clinical Trial Of CLBS03 For Type 1 Diabetes

Jan 18 (Reuters) - Caladrius Biosciences Inc <CLBS.O>::CALADRIUS BIOSCIENCES ANNOUNCES COMPLETION OF ENROLLMENT OF PHASE 2 T-REX CLINICAL TRIAL OF CLBS03 FOR TYPE 1 DIABETES.CALADRIUS BIOSCIENCES INC - TOPLINE DATA FROM PRIMARY ENDPOINT OF COMPLETED STUDY ON CLBS03 EXPECTED IN EARLY 2019.

Caladrius Biosciences reports 2017 third quarter results

Nov 9 (Reuters) - Caladrius Biosciences Inc <CLBS.O>:Caladrius Biosciences reports 2017 third quarter results.Q3 loss per share $0.38 from continuing operations.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up